Parkway Life REIT - DBS Research 2024-11-25: Prescription For Growth

• Parkway Life REIT (SGX:C2PU) is one of the top-performing S-REITs in Singapore with a share price return of >4x since its listing 12-13 years ago, with steady return in DPUs over the years.
• - Read this at SGinvestors.io -

Maiden entry into third key market.

• Parkway Life REIT announced its first acquisition in its third key market, Europe and UK, with the purchase of 11 nursing homes in France for S$159.9mil, slightly less than the property valuation of S$165.8mil. This was fully funded through an equity fund raising (EFR) via a private placement.
• - Read this at SGinvestors.io -
• The acquisition is expected to be completed by 4Q24 and is projected to generate a distribution per unit (DPU) accretion of ~1.4% and net asset value (NAV) accretion of ~4.3%.

Who is DomusVi, the vendor and master-lessee?

• Read more at SGinvestors.io.

Above is an excerpt from a report by DBS Group Research.
Clients of DBS may access the full PDF report @ https://www.dbs.com/insightsdirect/.

Read also DBS's most recent report:
2025-08-07 Parkway Life REIT - Defensive Core, With Catalysts On The Horizon.

Previous report by DBS:
2025-02-07 Parkway Life REIT - On A Solid Growth Trajectory.

Price targets by 2 other brokers at Parkway Life REIT Target Prices.

Listing of research reports at Parkway Life REIT Analyst Reports.

Relevant links:
Parkway Life REIT Share Price History,
Parkway Life REIT Announcements,
Parkway Life REIT Dividend Payout Dates & Corporate Actions,
Parkway Life REIT News